Roivant pivots towards cancer

The German company says it is getting a $10m upfront fee and is in line for development, regulatory, and commercial milestone payments that could reach $1bn across all four programmes. It will also be reimbursed for R&D costs and will pick up royalties on sales if any of the programmes reach the market.Cytovant is another example of a departure from Ramaswamy’s original vision of picking up drugs abandoned by other companies and giving them a new lease of life, in favour of licensing emerging therapies from other biotech players.

https://www.pmlive.com/pharma_news/roivant_forms_asian_cell_therapy_vant,_with_medigenes_help_1283643